Analyst Research

Report Title Price
Trading Report for (NVS). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
$58.00
Buy
Novartis AG (NVS) Profile and Financials, plus Nanotechnology Industry Trends Analysis, Operating Ratios and Financial Averages
Provider: Plunkett Research, Ltd.
$99.00
Buy
Novartis AG (NVS) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratios and Financial Averages
Provider: Plunkett Research, Ltd.
$99.00
Buy
Novartis AG (NVS) Profile and Financials, plus Biotechnology Industry Trends Analysis, Operating Ratios and Financial Averages
Provider: Plunkett Research, Ltd.
$99.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Novartis AG Reaffirms FY 2012 Revenue Outlook-Conference Call


Thursday, 19 Jul 2012 08:00am EDT 

Novartis AG announced that it made solid progress on its three strategic priorities in the second quarter and the Company's fiscal 2012 performance is on track so its outlook for fiscal 2012 remains unchanged. And that's group sales for fiscal 2012 are expected to be in line with fiscal 2011 in constant currency. The Company reported revenues of $58.566 billion in fiscal 2011. 

Latest Developments for Novartis AG

Latest Key Developments in Pharmaceuticals

Company Quote

Novartis AG
(NOVN.VX)
71.25
-0.2 -0.28%
11:31am EDT